硼替佐米瘤内递送对颅内胶质瘤模型生存的影响
该研究在U87和U251人胶质瘤细胞的皮下及颅内小鼠模型中评估硼替佐米递送方式对疗效的影响。体外纳摩尔浓度下胶质瘤细胞对硼替佐米敏感,皮下模型中静脉给药可减缓肿瘤进展,但颅内模型中全身给药不影响生存;经Alzet微型渗透泵将硼替佐米直接递送至颅内肿瘤部位则显著延长生存。作者认为绕开血脑屏障的瘤内给药是胶质瘤治疗的有效途径。
要点
- 体外纳摩尔浓度下U87和U251胶质瘤细胞对硼替佐米敏感。
- 皮下模型中静脉给予硼替佐米可减缓肿瘤进展。
- 颅内模型中全身给药不影响生存,而瘤内给药显著延长生存。
核心结论
- 使用渗透泵绕开血脑屏障可提高硼替佐米对颅内肿瘤的治疗效果,瘤内给予硼替佐米是胶质瘤治疗的有效途径。
研究设计与样本
- 研究使用U87和U251两种人胶质瘤细胞系,经荧光素酶标记后用于皮下和颅内体内肿瘤模型。
- 胶质瘤细胞接种于无胸腺裸鼠右侧腹皮下或额叶皮质颅内,颅内荷瘤小鼠植入含不同剂量硼替佐米的Alzet微型渗透泵,泵直接置入脑内瘤床,记录颅内荷瘤小鼠生存。
主要发现
- 体外纳摩尔浓度下胶质瘤细胞对硼替佐米敏感。
- 皮下异种移植模型中静脉给予硼替佐米可减缓肿瘤进展。
- 颅内胶质瘤模型中全身给予硼替佐米不影响生存。
- 颅内肿瘤部位给予硼替佐米的小鼠生存显著延长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE Glioblastoma (GBM) is the most prevalent and the most aggressive of primary brain tumors. There is currently no effective treatment for this tumor. The proteasome inhibitor bortezomib is effective for a variety of tumors, but not for GBM. The authors' goal was to demonstrate that bortezomib can be effective in the orthotopic GBM murine model if the appropriate method of drug delivery is used. In this study the Alzet mini-osmotic pump was used to bring the drug directly to the tumor in the brain, circumventing the blood-brain barrier; thus making bortezomib an effective treatment for GBM. METHODS The 2 human glioma cell lines, U87 and U251, were labeled with luciferase and used in the subcutaneous and intracranial in vivo tumor models. Glioma cells were implanted subcutaneously into the right flank, or intracranially into the frontal cortex of athymic nude mice. Mice bearing intracranial glioma tumors were implanted with an Alzet mini-osmotic pump containing different doses of bortezomib. The Alzet pumps were introduced directly into the tumor bed in the brain. Survival was documented for mice with intracranial tumors. RESULTS Glioma cells were sensitive to bortezomib at nanomolar quantities in vitro. In the subcutaneous in vivo xenograft tumor model, bortezomib given intravenously was effective in reducing tumor progression. However, in the intracranial glioma model, bortezomib given systemically did not affect survival. By sharp contrast, animals treated with bortezomib intracranially at the tumor site exhibited significantly increased survival. CONCLUSIONS Bypassing the blood-brain barrier by using the osmotic pump resulted in an increase in the efficacy of bortezomib for the treatment of intracranial tumors. Thus, the intratumoral administration of bortezomib into the cranial cavity is an effective approach for glioma therapy.
引用
- Wang W, Cho HY, Rosenstein-Sisson R, et al. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model. J Neurosurg. 2017. PMID: 28409734. doi:10.3171/2016.11.JNS161212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。